Advances in Cancer Immunotherapy™ - Webinars and Online Modules

As a component of the Society for Immunotherapy of Cancer's (SITC) regional, live Advances in Cancer Immunotherapy™ (ACI) programs, SITC is pleased to offer free online, introductory, CME-, CPE- and CNE-accredited programs via the society's online learning portal, SITC Cancer Immunotherapy connectED.These online activities provide an overview of basic immunology principles and the mechanisms and clinical applications of immunotherapy.

If you missed the opportunity to attend an Advances in Cancer Immunotherapy™ event, you can still obtain the education and CME, CPE and/or CNE credits through the Advances in Cancer Immunotherapy™ 2017 Video Series online modules.

Advances in Cancer Immunotherapy™ Online Program

Exemplar video presentations from the live ACI programs are used as content for the online, CE-certified classes.

You can now access the Advances in Cancer Immunotherapy™ 2017 Video Series. One video has been selected for each topic of the live ACI program. The class offers the following twelve modules for completion:

Module 1: Basic Principles of Cancer Immunotherapy
Module 2: Immunotherapy for the Treatment of Melanoma
Module 3: Immunotherapy for the Treatment of Lung Cancer
Module 4: Immunotherapy for the Treatment of Genitourinary Cancers
Module 5: Immunotherapy for the Treatment of Hematologic Malignancies
Module 6:Immunotherapy for the Treatment of Head and Neck Cancers
Module 7: Effective Practices for Incorporating Immunotherapy into Hospital Operations
Module 8: Coverage and Reimbursement Challenges and Strategies
Module 9: Mechanisms of Immune-Related Adverse Events
Module 10: Nursing Perspective on irAEs: Patient Education, Monitoring and Management
Module 11: Management and Mitigation of irAEs for Immunotherapy Prescribers
Module 12: Identification and Management of Immune-Related Adverse Events in the Emergency Setting

Click here to access this class to begin your online learning today!

ACI Homepage
PROGRAM PURPOSE
ACI Registration Information
Continuing Education Info
ACI Enduring Materials
Planning Committee

Advances in Cancer Immunotherapy™ Webinars

ACI Webinar Series

Log in to the free ACI webinars to learn about new treatment approvals and emerging scientific data relating to clinical applications of cancer immunotherapy. Hosted by experts in the field, the webinars provide an opportunity to continue your learning from this ACI program and interact with faculty during a dedicated question-and-answer session.

2018 Webinar Recordings

Advances in Cancer Immunotherapy^TM Webinar Series - Updates from the Field: ESMO Congress 2018 Clinical Trials

Advances in Cancer Immunotherapy^TM Webinar Series - Updates from the Field: Clinical Updates from SITC 2018

2019 Live Webinars
Dates coming soon!

Interactive Online Advances in Cancer Immunotherapy™ Classes

Participate in these short, interactive online classes to deepen your understanding of what you learned at today’s ACI program in cancer immunotherapy. Learn about specific disease states and practical barriers to implementation while engaging with case study examples. Each class will take approximately 30 minutes to complete and is also eligible for CME, CNE or CPE credits.

More information coming soon!

SITC Cancer Immunotherapy Guidelines Webinars

Ask questions as leading experts discuss the most recent immunotherapy treatment standards for specific disease states – stemming from SITC’s Cancer Immunotherapy Guidelines.

VIEW Cancer Immunotherapy Guideline WEBINARS On-Demand

Postgraduate Institute for Medicine SITC Logo

The 2018–2019 ACI series is jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

The 2018–2019 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from AbbVie Inc., Amgen Inc., AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, EMD Serono, Inc. and Pfizer Inc., Genentech, Incyte Corporation, Lilly USA, LLC, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc. and Prometheus Laboratories Inc. (as of Aug. 21, 2018).